Maxwell Biosciences Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $20M

  • Investors
  • 31

Maxwell Biosciences General Information

Description

Operator of a drug platform company intended to create biomimetic therapeutics and synthetic compounds that mimic and improve upon biomolecules. The company's platform effectively destroys viruses, bacteria, fungi, and some cancers while avoiding healthy cells in human tissues and animal studies, where compounds imitate key immune system components, enabling healthcare professionals to treat formerly untreatable conditions.

Contact Information

Formerly Known As
Health Anonymous
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3809 Juniper Trace
  • Suite 101
  • Austin, TX 78738
  • United States
+1 (855)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 3809 Juniper Trace
  • Suite 101
  • Austin, TX 78738
  • United States
+1 (855)

Maxwell Biosciences Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Maxwell Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 05-Aug-2025 $20M Completed Pre-Clinical Trials
7. Secondary Transaction - Private Completed Pre-Clinical Trials
6. Later Stage VC Cancelled Pre-Clinical Trials
5. Seed Round 01-Oct-2023 Completed Pre-Clinical Trials
4. Accelerator/Incubator 14-Oct-2022 Completed Pre-Clinical Trials
3. Grant 01-Sep-2021 Completed Pre-Clinical Trials
2. Seed Round 30-Jun-2021 $4.7M $4.7M Completed Pre-Clinical Trials
1. Grant $35M Completed Startup
To view Maxwell Biosciences’s complete valuation and funding history, request access »

Maxwell Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-1
Seed-5
Seed-7
Seed-6
Seed-4
Seed-3 1,200,000 $0.000010 $0.1 $0.1 1x $0.1 1.47%
Seed-2 8,700,000 $0.000010 $0.07 $0.07 1x $0.07 10.69%
To view Maxwell Biosciences’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Maxwell Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a drug platform company intended to create biomimetic therapeutics and synthetic compounds that mimic and im
Drug Discovery
Austin, TX
22 As of 2026

Paris, France
 

Wilmington, DE
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Maxwell Biosciences Competitors (5)

One of Maxwell Biosciences’s 5 competitors is Abivax, a Formerly PE-Backed company based in Paris, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abivax Formerly PE-Backed Paris, France
NiKang Therapeutics Venture Capital-Backed Wilmington, DE
Molecular Partners Formerly VC-backed Zurich, Switzerland
Moderna France Formerly PE-Backed Lucon, France
Glaxosmithkline Biologicals Corporation Saint-Amand-Les-Eaux, France
You’re viewing 5 of 5 competitors. Get the full list »

Maxwell Biosciences Patents

Maxwell Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026136558-A1 Peptoids for inhibition of nasal pathogen infections, and compositions and methods for administration thereof Pending 20-Dec-2024
US-20250282821-A1 Lipopolysaccharide-binding peptoids, and compositions and methods of use thereof Pending 08-Mar-2024
WO-2025189073-A1 Lipopolysaccharide-binding peptoids, and compositions and methods of use thereof Pending 08-Mar-2024
WO-2025189073-A8 Lipopolysaccharide-binding peptoids, and compositions and methods of use thereof Pending 08-Mar-2024
US-20250268809-A1 Broad-spectrum peptoids for oral and dental hygiene, and compositions and methods of use thereof Pending 23-Feb-2024 A61K38/08
To view Maxwell Biosciences’s complete patent history, request access »

Maxwell Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Maxwell Biosciences Investors (31)

Investor Name Investor Type Holding Investor Since Participating Rounds
Transform Investments Venture Capital Minority
3Rodeo Venture Capital Minority
Accelerator Venture Partners Venture Capital Minority
Angel Star Ventures Angel Group Minority
Angel (individual) Minority
You’re viewing 5 of 31 investors. Get the full list »

Maxwell Biosciences FAQs

  • When was Maxwell Biosciences founded?

    Maxwell Biosciences was founded in 2016.

  • Where is Maxwell Biosciences headquartered?

    Maxwell Biosciences is headquartered in Austin, TX.

  • What is the size of Maxwell Biosciences?

    Maxwell Biosciences has 22 total employees.

  • What industry is Maxwell Biosciences in?

    Maxwell Biosciences’s primary industry is Drug Discovery.

  • Is Maxwell Biosciences a private or public company?

    Maxwell Biosciences is a Private company.

  • What is Maxwell Biosciences’s current revenue?

    The current revenue for Maxwell Biosciences is .

  • How much funding has Maxwell Biosciences raised over time?

    Maxwell Biosciences has raised $35.6M.

  • Who are Maxwell Biosciences’s investors?

    Transform Investments, 3Rodeo, Accelerator Venture Partners, Angel Star Ventures, and are 5 of 31 investors who have invested in Maxwell Biosciences.

  • Who are Maxwell Biosciences’s competitors?

    Abivax, NiKang Therapeutics, Molecular Partners, Moderna France, and Glaxosmithkline Biologicals are competitors of Maxwell Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process